BioSpace News Archive

Today, the U.S. Food and Drug Administration approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1), whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations.

POXEL SA announced the drawdown of the remaining two tranches of the convertible bonds as part of the equity-linked financing facility with Iris Capital Investment representing a total of EUR 2 million.

InnerScope Hearing Technologies Inc., an emerging and disruptive leader in the Over-the-Counter Hearing Aid space announced its subsidiary HearingAssist, America’s #1 Affordable OTC Hearing Aid Brand had launched its FDA-Registered Over-the-Counter Rechargeable Hearing Aids on CVS.com.

Stemtech Corporation (OTCQB:STEK) today announced that Life Factor Research, the Research and Development Division of Stemtech, has acquired its first contract to produce a while label product for a new client.

The American Cancer Society and the Richard M. Schulze Family Foundation announced the launch of a $10 million challenge grant to benefit five American Cancer Society Hope Lodges – in Omaha, NE; Charleston, SC; Lexington, KY; Lubbock, TX; and Kansas City, MO.

Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the company has received a No Objection Letter from Health Canada

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 5, 2023.

Galapagos NV announced changes in the Executive Committee effective 1 January 2023.

Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States. Patients with the condition typically have inflammation throughout their esophagus and trouble swallowing food – known as dysphagia.

Lipella Pharmaceuticals Inc. (“Lipella,” “our, “us” or the “Company”), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced the closing of its initial public offering of 1,217,391 shares of its common stock at a price to the public of $5.75 per share.